Safety of calcineurin inhibitors in the management of lichen sclerosis.
Lewis
F M
FM
Neill
S M
SM
D065095:Calcineurin Inhibitors; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D018459:Lichen Sclerosus et Atrophicus / Q000188:drug therapy*; D008297:Male; D016559:Tacrolimus / Q000009:adverse effects*
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D016559:Tacrolimus